Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jan 17;4(1):100901.
doi: 10.1016/j.xcrm.2022.100901.

Illuminating the mechanism of IL-6-mediated immunotherapy resistance

Anna E Vilgelm  1
Affiliations
Comment

Illuminating the mechanism of IL-6-mediated immunotherapy resistance

Anna E Vilgelm. Cell Rep Med. .

Abstract

Huseni et al. report that IL-6-STAT3 signaling negatively impacts the anti-tumor function of cytotoxic T cells. Targeting IL-6 signaling may enhance tumor responses to immune checkpoint blockade therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Comment on

  • CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy.
    Huseni MA, Wang L, Klementowicz JE, Yuen K, Breart B, Orr C, Liu LF, Li Y, Gupta V, Li C, Rishipathak D, Peng J, Şenbabaoǧlu Y, Modrusan Z, Keerthivasan S, Madireddi S, Chen YJ, Fraser EJ, Leng N, Hamidi H, Koeppen H, Ziai J, Hashimoto K, Fassò M, Williams P, McDermott DF, Rosenberg JE, Powles T, Emens LA, Hegde PS, Mellman I, Turley SJ, Wilson MS, Mariathasan S, Molinero L, Merchant M, West NR. Huseni MA, et al. Cell Rep Med. 2023 Jan 17;4(1):100878. doi: 10.1016/j.xcrm.2022.100878. Epub 2023 Jan 3. Cell Rep Med. 2023. PMID: 36599350 Free PMC article.

References

    1. Huseni M.A., Wang L., Klementowicz J.E., Yuen K., Breart B., Orr C., Liu L.-f., Li Y., Gupta V., Li C., et al. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep. Med. 2022;4:100878. - PMC - PubMed
    1. Tanaka T., Narazaki M., Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 2014;6:a016295. doi: 10.1101/cshperspect.a016295. - DOI - PMC - PubMed
    1. Johnson D.E., O'Keefe R.A., Grandis J.R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 2018;15:234–248. doi: 10.1038/nrclinonc.2018.8. - DOI - PMC - PubMed
    1. Yu H., Lee H., Herrmann A., Buettner R., Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer. 2014;14:736–746. doi: 10.1038/nrc3818. - DOI - PubMed
    1. Laino A.S., Woods D., Vassallo M., Qian X., Tang H., Wind-Rotolo M., Weber J. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J. Immunother. Cancer. 2020;8:e000842. doi: 10.1136/jitc-2020-000842. - DOI - PMC - PubMed